Anti-Mouse CD178 (FasL) – Purified in vivo PLATINUM™ Functional Grade

B6 mouse FasL cDNA-transfected baby hamster kidney (B6 FasL/BHK) cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone MFL3 recognizes an epitope on mouse FasL.

FasL antibody, clone AFS98, recognizes Fas ligand (FasL), also known as CD178, Apo-1 ligand, and CD95 ligand. FasL is a 40 kDa type II integral membrane protein that belongs to the tumor necrosis factor (TNF) superfamily. FasL is expressed by activated T cells and natural killer (NK cells)^1-3. Binding of FasL to its receptor Fas (CD95, APO-1) induces apoptotic cell death in Fas-expressing target cells, contributing to anti-viral immunity. FasL also contributes to peripheral tolerance and the downregulation of immune responses through activation-induced autocrine and paracrine T cell death⁴. FasL is also found in the anterior chamber of the eye and on Sertoli cells in the testis, and is implicated in immune-privilege at these sites^5,6. FasL also contributes to CD8 proliferation and neutrophil recruitment^7,8. Soluble FasL (26 kDa) can be released following cleavage by metalloproteinases and block FasL-mediated signaling⁹. Fas/FasL-signaling is involved in the development of many human diseases, including autoimmunity and cancer10. Many human tumors over-express FasL, resulting in tumor infiltrating lymphocyte (TIL) apoptosis and immune evasion, which is associated with poor prognosis^11-14.

FasL is expressed on activated T cells, NK cells, the eye, and testis.

Fas (CD95)

1. Okumura K., et al. (1994) Proc Natl Acad Sci USA. 91:4930–4934
2. Nagata S., et al. (1995) J Immunol. 154:3806–3813
3. Saito T., et al. (1995) J Exp Med. 181:1235–1238
4. Ferguson T A., et al. (1995) Science. 270:1189–1192
5. Duke R C., et al. (1995) Nature (London). 377:630–632
6. Fink PJ. (2000) J Immunol. 165(10):5537-43
7. Matsuzawa A., et al. (1998) J Immunol. 161: 4484–4488
8. Nagata S., et al. (1998) Nat Med. 4(1):31-6
9. Hueber AO., et al (2019) Cancers (Basel). 11(5):639
10. Kabelitz D., et al. (2000) Cancer Res. 60: 822–828
11. Giannarelli D., et al. (2000) Int J Cancer. 89: 127–132
12. Kanno H., et al. (2000) Br J Cancer. 82: 1446–1452.
13. Nagano H., et al. (Cancer) Br J Cancer. 82: 1211–1217